← All organizations

WuXi

For profitWebsite ↗

Also known as: BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. | D3 Bio (Wuxi) Co., Ltd | WUXI | WuXi CDS Clinical Research (Shanghai) Co.Ltd. | Wuxi Cellular Biopharmaceutical Group Ltd. | WuXi Clinical

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 3

First clinical trial

First marketed drug

Last known activity

Jul 11, 2025

Timeline

2000s

Dec 1, 2000
WuXi— Founded

2010s

Oct 17, 2017
ResearchPoint Global— Acquired

2020s

Nov 7, 2024
mycophenolate— Marketing Organization

Drugs by trial phase (15 distinct, 14 trials)

Phase 3 (7 own, 1 via acquisition)

Phase 2 (2 own, 3 via acquisition)

Phase 1 (2 own, 0 via acquisition)

Indications

Studied for

Carcinoma, Non-Small-Cell Lung

Marketed drugs (1)

mycophenolate

Subsidiaries (1 direct, 1 total across the full acquisition tree)

ResearchPoint Global

Recent trials (12)

NCT07093398Lead sponsorPhase 1Jul 11, 2025
NCT06716203CollaboratorPhase 3Dec 1, 2024
NCT06716216CollaboratorPhase 3Dec 1, 2024
NCT06570291Lead sponsorPhase 3Oct 31, 2024
NCT06704581Lead sponsorPhase 3Oct 28, 2024
NCT05957536Lead sponsorPhase 1Sep 19, 2023
NCT05886920Lead sponsorPhase 1Jul 10, 2023
NCT05794204CollaboratorPhase 2Jun 9, 2023
NCT05410145Lead sponsorPhase 1Aug 3, 2022
NCT05410145Study directorPhase 1Aug 3, 2022
NCT05068024CollaboratorPhase 1/Phase 2Aug 23, 2021
NCT02954172CollaboratorPhase 3Nov 1, 2016

Details

Founded: Shanghai, CN Dec 1, 2000
Last known activity: Jul 11, 2025

Notes

CRO